connexin 46 CRISPR Activation Plasmid (h): sc-403947-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- connexin 46 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- connexin 46 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by connexin 46 CRISPR Activation Plasmid (h) and connexin 46 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the GJA3 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: connexin 46 Antibody (C-3): sc-365394
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
connexin 46 CRISPR Activation Plasmid (h) | sc-403947-ACT | 20 µg | $397.00 | |||
connexin 46 CRISPR Activation Plasmid (h2) | sc-403947-ACT-2 | 20 µg | $397.00 |
GJA3 encodes connexin 46, a lens-enriched gap junction protein that assembles into hemichannels and intercellular channels to enable direct cell–cell exchange of ions and metabolites. By supporting lens fiber cell coupling, connexin 46 helps maintain ionic homeostasis, redox balance, and metabolic coordination required for lens transparency. Altered connexin 46 function disrupts gap junction communication and is associated with hereditary cataract phenotypes and impaired lens physiology. In cell models, GJA3 activity is commonly studied in the context of membrane trafficking, channel gating, and stress-responsive pathways that influence proteostasis and oxidative damage.
connexin 46 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous GJA3 expression without altering the underlying DNA sequence.
connexin 46 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the GJA3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the GJA3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous connexin 46 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native GJA3 locus and enabling the study of connexin 46-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of connexin 46 pathway restoration in tumor cells with silenced or reduced GJA3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.